Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Sell

C

Fortress Biotech, Inc. (FBIO)

Pharmaceutical Preparations

https://www.fortressbiotech.com

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

1111 KANE CONCOURSE, SUITE 301
BAY HARBOR ISLANDS, FL

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/17/2011

Market Cap

37,762,385

Shares Outstanding

18,380,000

Weighted SO

18,376,750

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

MBIO --.--%

ACHL --.--%

APTO --.--%

FBIOP --.--%

CKPT --.--%

ATXI --.--%

PIRS --.--%

ALRN --.--%

RVPHW --.--%

Beta

1.7330

Last Div

0.0000

Range

1.24-7.2

Chg

-0.0500

Avg Vol

249112

Mkt Cap

37762385

Exch

NASDAQ

Country

US

Phone

781 652 4500

DCF Diff

2.1612

DCF

-0.1611

Div Yield

0.0000

P/S

0.4573

EV Multiple

-0.5386

P/FV

1.8955

Div Yield %

0.0000

P/E

-0.7465

PEG

-0.0308

Payout

-0.1927

Current Ratio

1.3692

Quick Ratio

1.2410

Cash Ratio

1.0087

DSO

47.2432

DIO

135.0659

Op Cycle

182.3091

DPO

529.2347

CCC

-346.9256

Gross Margin

0.6830

Op Margin

-1.1839

Pretax Margin

-0.8508

Net Margin

-0.5497

Eff Tax Rate

0.0536

ROA

-0.3116

ROE

-2.2663

ROCE

-1.3939

NI/EBT

0.6461

EBT/EBIT

0.7186

EBIT/Rev

-1.1839

Debt Ratio

0.4976

D/E

4.0548

LT Debt/Cap

0.7894

Total Debt/Cap

0.8022

Int Coverage

73.4002

CF/Debt

-1.3649

Equity Multi

8.1493

Rec Turnover

7.7260

Pay Turnover

0.6897

Inv Turnover

2.7024

FA Turnover

4.5445

Asset Turnover

0.5669

OCF/Share

-5.4015

FCF/Share

-5.4596

Cash/Share

4.1602

OCF/Sales

-1.1981

FCF/OCF

1.0108

CF Coverage

-1.3649

ST Coverage

-18.0513

CapEx Coverage

-92.9878

Div&CapEx Cov

-10.0824

P/BV

1.8955

P/B

1.8955

P/S

0.4573

P/E

-0.7465

P/FCF

-0.3776

P/OCF

-0.3425

P/CF

-0.3425

PEG

-0.0308

P/S

0.4573

EV Multiple

-0.5386

P/FV

1.8955

DPS

0.0000

Latest Headlines (EST)

Benzinga Dec 29, 12:19 Nasdaq Down Over 100 Points; Fortress Biotech Shares Plummet GlobeNewswire Inc. Dec 29, 08:20 Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules GlobeNewswire Inc. Dec 06, 08:30 Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd. Benzinga Nov 29, 12:00 Roth MKM Maintains Buy Rating for Fortress Biotech: Here's What You Need To Know PennyStocks Nov 20, 10:17 Best Penny Stocks To Buy This Week? 4 To Watch Now PennyStocks Nov 17, 13:32 11 Top Penny Stocks To Buy Now According To Insiders PennyStocks Nov 17, 13:32 11 Top Penny Stocks To Buy Now According To Insiders GlobeNewswire Inc. Nov 10, 08:15 Fortress Biotech Announces Pricing of $10.0 Million Public Offering GlobeNewswire Inc. Nov 09, 17:05 Fortress Biotech Announces Launch of Proposed Public Offering GlobeNewswire Inc. Oct 31, 08:30 Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

Revenue Product Segmentation